Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib
| العنوان: | Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib |
|---|---|
| المؤلفون: | Nifasha Rusibamayila, Harish Seethapathy, Riley Fadden, Ivy A. Rosales, Ian A. Strohbehn, Kenar D. Jhaveri, Meghan E. Sise, Ryan J. Sullivan, Kerry L. Reynolds, Robert B. Colvin, Howard L. Kaufman, Orhan Efe, Meghan Lee, Donald F. Chute |
| المصدر: | Nephrol Dial Transplant |
| بيانات النشر: | Oxford University Press (OUP), 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Pyridones, Pyrimidinones, urologic and male genital diseases, 03 medical and health sciences, Liver disease, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Oximes, medicine, Humans, 030212 general & internal medicine, Melanoma, Retrospective Studies, Trametinib, Transplantation, urogenital system, business.industry, Incidence (epidemiology), Imidazoles, Acute kidney injury, Dabrafenib, Retrospective cohort study, Acute Kidney Injury, medicine.disease, female genital diseases and pregnancy complications, Nephrology, 030220 oncology & carcinogenesis, Mutation, Cohort, Original Article, Chills, medicine.symptom, business, medicine.drug |
| الوصف: | Background Our objective was to characterize the incidence, risk factors and clinical features of acute kidney injury (AKI) in patients receiving dabrafenib and trametinib. Methods We performed a retrospective cohort study examining the kidney outcomes of patients in a large healthcare system who received dabrafenib/trametinib between 2010 and 2019. The primary outcome was AKI, defined as a 1.5-fold increase in serum creatinine from baseline within a 12-month study period. AKI severity and etiology was determined for each case by chart review. Logistic regression was used to evaluate baseline predictors of AKI. Results A total of 199 patients who received dabrafenib in our healthcare system from 2010 to 2019 were included in the analysis. Forty-two patients (21%) experienced AKI within 12 months; 10 patients (5% of the total cohort, 24% of AKI patients) experienced AKI occurring during a dabrafenib/trametinib-induced febrile syndrome characterized by fever, chills, gastrointestinal symptoms and elevated liver enzymes. Preexisting liver disease was the only significant predictor of AKI in the cohort. One patient had biopsy-proven granulomatous acute interstitial nephritis that resolved with corticosteroids. Conclusions Oncologists and nephrologists should be aware that AKI is common after dabrafenib/trametinib and a substantial number of cases occur in the setting of treatment-induced pyrexia. |
| تدمد: | 1460-2385 0931-0509 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::832c205ff87f9dee9c8944cf17e78481 https://doi.org/10.1093/ndt/gfaa372 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....832c205ff87f9dee9c8944cf17e78481 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14602385 09310509 |
|---|